Johnson & Johnson的阿尔茨海默氏老年痴呆症药物posdinemab未能减缓早期病人认知下降的速度,阻止其发展。 Johnson & Johnson's Alzheimer's drug posdinemab failed to slow cognitive decline in early-stage patients, halting its development.

Johnson & Johnson的实验性阿尔茨海默氏病的药物posdinemab在关键阶段的第二阶段试验中未能显示出重大的认知效益, Johnson & Johnson's experimental Alzheimer's drug posdinemab has failed to show significant cognitive benefits in a pivotal phase 2 trial, dealing a major blow to hopes for a new treatment targeting tau protein buildup in the brain. 这些结果于2025年11月24日公布, 显示抗托氏抗体与安慰剂相比, 早期阿尔茨海默氏症患者的认知下降并没有减缓, 促使该公司重新评估其发展道路。 The results, announced on November 24, 2025, indicate the anti-tau antibody did not slow cognitive decline in patients with early Alzheimer's compared to placebo, prompting the company to reassess its development path. 这一结果标志着在寻求有效的阿尔茨海默氏疗法方面又一个挫折,尽管投资巨大,期望很高。 The outcome marks another setback in the search for effective Alzheimer's therapies, despite heavy investment and high expectations.